AR051990A1 - Omega-feniloctanamidas - Google Patents

Omega-feniloctanamidas

Info

Publication number
AR051990A1
AR051990A1 ARP050105155A ARP050105155A AR051990A1 AR 051990 A1 AR051990 A1 AR 051990A1 AR P050105155 A ARP050105155 A AR P050105155A AR P050105155 A ARP050105155 A AR P050105155A AR 051990 A1 AR051990 A1 AR 051990A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
alkylamino
hydroxy
carbamoyl
Prior art date
Application number
ARP050105155A
Other languages
English (en)
Original Assignee
Speedel Experimenta Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speedel Experimenta Ag filed Critical Speedel Experimenta Ag
Publication of AR051990A1 publication Critical patent/AR051990A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Los compuestos de la presente tienen propiedades inhibidoras de renina y pueden ser empleados como medicamentos. Reivindicacion 1: Compuesto de la formula (1) en la cual R1 es arilo opcionalmente substituido; R2 es alquilo C1-8, alquenilo C2-8 o cicloalquilo C3-8 o es fenil- o naftil-alquilo C1-4, cada uno de los cuales está sin substituir o está mono-, di- o trisubstituido con alquilo C1-4, alcoxilo C1-4, hidroxilo, alquilamino C1-4, N,N-dialquilamino C1-4, halogeno y/o trifluormetilo; R3 es H, alquilo C1-4 o alcanoílo C1-8; R4 es H, alquilo C1-4 o alcanoílo C1-8; R5 son cada uno independientemente H, alquilo C1-8 o, conjuntamente con el átomo de C al cual están unidos, un radical cicloalquilideno C3-8; R6 es H o hidroxilo; R son cada uno independientemente 1-4 radicales seleccionados de: H, halogeno, alquilo C1-8, cicloalquilo de 3 a 8 miembros, polihaloalquilo C1-4, polihaloalcoxilo C1-4, alcoxi C1-4- alquilo C1-4, alcoxi C1-4-alcoxi C1-4-alquilo C1-4, cicloalcoxi de 3 a 8 miembros-alquilo C1-4, hidroxilo, alcanoiloxi C1-8-alquilo C1-4, hidroxi-alquilo C2-8, alquiltio C1-4-alquilo C1-4, alcano C1-8-sulfonil-alquilo C1-4, tiazoliltio-alquilo C1-4, tiazoliniltio-alquilo C1-4, imidazoliltio-alquilo C1-4, tioalquilo C1-4 opcionalmente oxidado en N-piridil, pirimidiniltio-alquilo C1-4, piridil o N-oxidopiridilalquilo C1-4, parcial y opcionalmente hidrogenados, alcano C1-4-sulfonilamino-alquilo C1-4, trifluoralcano C1-8-sulfonilamino-alquilo C1-4, pirrolidino- alquilo C1-4, piperidino-alquilo C1-4, piperazino-alquilo C1-4, N'-alquil C1-4-piperazino-alquilo C1-4, N'-alcanoil C2-8-piperazino-alquilo C1-4, morfolino-alquilo C1-4, tiomorfolino-alquilo C1-4, S-oxotiomorfolino-alquilo C1-4, S,S-dioxotiomorfolino- alquilo C1-4, ciano-alquilo C1-4, carboxi-alquilo C1-4, alcoxi C1-4-carbonil-alquilo C1-4, carbamoil-alquilo C1-8, N-mono- o N,N-dialquil C1-4-carbamoil-alquilo C1-4, fenilo opcionalmente mono-, di- o trisubstituido con alquilo C1-4, alcoxilo C1-4, hidroxilo, alquilamino C1-4, di-alquilamino C1-4, halogeno y/o trifluormetilo, naftilo opcionalmente mono-, di- o trisubstituido con alquilo C1-4, alcoxilo C1-4, hidroxilo, alquilamino C1-4, di- alquilamino C1-4, halogeno y/o trifluormetilo, hidroxi- alcoxilo C2-8, halo(hidroxi)alcoxilo C2-8, alcano C1-8-sulfonil-(hidroxi)alcoxilo C1-4, amino-alquilo C1-4, alquil C1-4-amino-alquilo C1-4, N,N-di-alquil C1-4-amino-alquilo C1-4, N-alcanoil C1-4-amino-alquilo C1-4, alcoxi C1-8-carbonilamino-alquilo C2-8, aminoalcoxilo C1-4, alquil C1-4-amino-alcoxilo C1-4, N,N-di-alquil C1-4-amino-alcoxilo C1-4, alcanoil C1-8-amino-alcoxilo C1-4, alcoxi C1-8-carbonil-amino-alcoxilo C2-8, alcanoil C1-8-alcoxilo C2-4 que lleva el grupo alcanoilo más arriba de la posicion alfa, alcoxilo C1-8, cicloalcoxilo de 3 a 8 miembros, alqueniloxilo C2-8, cicloalcoxi de 3 a 8 miembros-alcoxilo C1-4, alcoxi C1-4-alcoxilo C1-4, alcoxi C1-4-alquenilo C2-4, alqueniloxi C2-8-alcoxilo C1-4, alcoxi C1-4-alqueniloxilo C2-4, alqueniloxi C2-8-alquilo C1-4, alquil C1-4-tio-alcoxilo C1-4, alcano C1-8-sulfonilamino-alcoxilo C1-4, alquil C1-4-tio-(hidroxi)alcoxilo C1-4, fenil-alcoxilo C1-4 opcionalmente mono-, di- o trisubstituido con alquilo C1-4, alcoxilo C1-4, hidroxilo, alquilamino C1-4, di-alquilamino C1-4, halogeno y/o trifluormetilo, naftil-alcoxilo C1-4 opcionalmente mono-, di- o trisubstituido con alquilo C1-4, alcoxilo C1-4, hidroxilo, alquilamino C1-4, di- alquilamino C1-4, halogeno y/o trifluormetilo, cada uno de los cuales está sin substituir o mono-, di- o trisubstituido con alquilo C1-4, alcoxilo C1-4, hidroxilo, alquilamino C1-4, di-alquilamino C1-4, halogeno y/o trifluormetilo, polihaloalcoxilo C1-4, piridil o N-oxidopiridil- alcoxilo C1-4 parcial y opcionalmente hidrogenados, tiazolil-alcoxilo C1-4, morfolino alcoxilo C1-4 opcionalmente oxidado en N, tiazolil-tio- alcoxilo C1-4, tiazolinil-tio-alcoxilo C1-4, imidazolil-tio-alcoxilo C1-4, piridil-tio-alcoxilo C1-4 opcionalmente oxidado en N, pirimidinil-tio- alcoxilo C1-4, alcano C1-8-sulfonil-alcoxilo C1-4, trifluoralcano C1-8-sulfonilamino-alcoxilo C1-4, pirrolidino-alcoxilo C1-4, piperidino- alcoxilo C1-4, ciano-alcoxilo C1-4, carboxi-alcoxilo C1-4, alcoxi C1-4-carbonil-alcoxilo C1-4, carbamoil-alcoxilo C1-4, N-alquil C1-8- carbamoil-alcoxilo C1-4, N-mono- o N,N-dialquil C1-4-carbamoil-alcoxilo C1-4, carboxi-alquilo C1-4, alcoxi C1-4-carbonil-alquilo C1-4, carbamoil-alquilo C1-8, N-mono- o N,N-dialquil C1-4-carbamoil-alquilo C1-4, carboxi-alcoxilo C1-4, alcoxi C1-4-carbonil-alcoxilo C1-4, carbamoil-alcoxilo C1-8, alquilamino C1-4 o N,N-dialquilamino C1-4; y su sal, especialmente sal farmacéuticamente util del mismo.
ARP050105155A 2004-12-10 2005-12-09 Omega-feniloctanamidas AR051990A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH20482004 2004-12-10

Publications (1)

Publication Number Publication Date
AR051990A1 true AR051990A1 (es) 2007-02-21

Family

ID=36088490

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105155A AR051990A1 (es) 2004-12-10 2005-12-09 Omega-feniloctanamidas

Country Status (13)

Country Link
US (1) US7615664B2 (es)
EP (1) EP1819663B1 (es)
JP (1) JP2008523035A (es)
CN (1) CN101076511A (es)
AR (1) AR051990A1 (es)
AT (1) ATE389633T1 (es)
BR (1) BRPI0518998A2 (es)
CA (1) CA2590247A1 (es)
DE (1) DE602005005518T2 (es)
HK (1) HK1110065A1 (es)
IL (1) IL183770A0 (es)
TW (1) TW200631929A (es)
WO (1) WO2006061426A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0505969D0 (en) 2005-03-23 2005-04-27 Novartis Ag Organic compounds
AR058885A1 (es) 2005-12-30 2008-02-27 Novartis Ag Compuestos de piperidina 3,5-sustituidos
EP1872780A3 (en) * 2006-06-14 2008-04-30 Speedel Experimenta AG Omega-Phenyloctanamides as therapeutic compounds
EP2527338B1 (en) 2007-06-25 2015-05-06 Novartis AG N5-(2-ethoxyethyl)-n3-(2-pyridinyl) -3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
DE102008009623A1 (de) 2008-02-18 2009-08-20 Kaltenbach & Voigt Gmbh Vorrichtung zum Betreiben eines elektrisch betriebenen medizinischen Instruments

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3061205D1 (en) * 1979-06-16 1983-01-05 Beecham Group Plc Secondary amines, their preparation and use in pharmaceutical compositions
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5659065A (en) * 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
CA2412452C (en) * 2000-07-25 2008-12-30 Speedel Pharma Ag Process for the preparation of substituted octanoyl amides
US20030114389A1 (en) * 2001-11-13 2003-06-19 Webb Randy Lee Combination of organic compounds
US20060154926A1 (en) * 2002-06-11 2006-07-13 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease using aryl alkanoic acid amides
EP1689702B1 (en) * 2003-11-26 2013-01-30 Novartis AG Organic compounds
EP1577292A1 (en) * 2004-03-17 2005-09-21 Pfizer Limited Phenylaminoethanol derivatives as beta2 receptor agonists
PT1717226E (pt) 2004-03-19 2009-04-03 Novartis Ag Derivados de 5-amino-4-hidroxi-8-(1h-indol-5-il)-octan amida 2,7-substituída como inibidores da renina para o tratamento da hipertensão
WO2005092840A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Formamide derivatives useful as adrenoceptor

Also Published As

Publication number Publication date
EP1819663A1 (en) 2007-08-22
US7615664B2 (en) 2009-11-10
DE602005005518D1 (de) 2008-04-30
WO2006061426A1 (en) 2006-06-15
CA2590247A1 (en) 2006-06-15
BRPI0518998A2 (pt) 2008-12-23
TW200631929A (en) 2006-09-16
EP1819663B1 (en) 2008-03-19
US20080153902A1 (en) 2008-06-26
CN101076511A (zh) 2007-11-21
ATE389633T1 (de) 2008-04-15
HK1110065A1 (en) 2008-07-04
IL183770A0 (en) 2007-09-20
JP2008523035A (ja) 2008-07-03
DE602005005518T2 (de) 2009-04-23

Similar Documents

Publication Publication Date Title
AR051990A1 (es) Omega-feniloctanamidas
CR8831A (es) Compuestos y metodos para el tratamiento de dislipidemia
AR055212A1 (es) Compuestos heterociclicos como bloqueantes del canal ionico p2x7
AR054090A1 (es) Derivados de quinuclidina como antagonistas del receptor muscarinico m3. composiciones farmaceuticas y proceso de obtencion
AR057702A1 (es) Inhibidores macrociclicos del virus de la hepatitis c, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para la profilaxis o el tratamiento de infecciones por flavivirus
AR075717A1 (es) Compuestos de 3- aril quinazolin -4- ona para combatir plagas de invertebrados
AR058699A1 (es) Derivados de sulfonamidoanilina como inhibidores de tirosina-quinasas jak-2 y jak-3
BR112015025716A2 (pt) pró-fármacos de nucleosídeo submetidos a deutério úteis para o tratamento de hcv
AR078152A1 (es) Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden
AR059905A1 (es) Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto
CO2021015624A2 (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituída, composiciones de estos y métodos de tratamiento con dichos compuestos
TW200720266A (en) Benzodioxane and benzodioxolan derivatives and uses thereof
PE20081441A1 (es) Subtipo de amidas selectivas de diazabicicloalcanos
NI201300113A (es) Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y métodos de tratamiento con las mismas.
EA201592082A1 (ru) 3,4-дигидроизохинолин-2(1h)-ильные соединения
AR073774A1 (es) Compuestos antibioticos oxazolidinona triciclicos
PE20060483A1 (es) Compuestos heterociclicos como antagonistas de nk1
CO6210724A2 (es) Compuesto heterociclico y composicion farmaceutica del mismo
AR060535A1 (es) Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina
AR068466A1 (es) Cianoisoquinolina
PE20061197A1 (es) Aminoalcoholes triciclicos, como inhibidores de la secresion de citoquina il-8
AR082454A1 (es) Proceso para producir compuestos aromaticos de carbonilo e imina
BRPI0911679B8 (pt) composto aciltioureia ou um sal do mesmo, uso do dito composto para tratar câncer, bem como agente farmacêutico, agente antitumoral e composição farmacêutica compreendendo dito composto
PE20080182A1 (es) Derivados pirrolo-quinoxalinona como antibacterianos
AR057148A1 (es) Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias

Legal Events

Date Code Title Description
FB Suspension of granting procedure